Description of a new species and two new records of the family Cosmopterigidae (Lepidoptera) from Korea.

Three species belonging to the family Cosmopterigidae are treated: Anatrachyntis koreana sp. nov. is described as new to science, Anatrachyntis ptilodelta (Meyrick, 1922) and Macrobathra nomaea Meyrick, 1914 are reported for the first time in Korea.

Discovery of Bucculatrix koreana sp. nov. and newly recorded Bucculatrix duanwuia (Lepidoptera: Bucculatricidae) in Korea.

In this study, we describe a new species, Bucculatrix koreana sp. nov., and report B.

Effects of pharmacist-led home visit services and factors influencing medication adherence improvement.

Background: The use of medicines is crucial in treatment, but nonadherence poses an important challenge, particularly when managing polypharmacy and long-term conditions. Pharmacist-led home visit services offer a promising solution to enhance the outcomes associated with medication use. However, the effects and the factors contributing to this improvement remain unclear.

The price of dialysis access: Implications of access type and patient-centric approaches to cost.

Purpose: This study explores out-of-pocket (OOP) costs for patients and provider reimbursement for dialysis access creation. It aims to illustrate the financial characteristics of four dialysis access modalities to consider in decision-making for clinicians, patients, and payers.

Materials And Methods: Retrospective data from the Merative™ MarketScan Commercial Claims and Encounters Databases from 2017 to 2022 was analyzed for patients who received an arteriovenous fistula (AVF), arteriovenous graft (AVG), peritoneal dialysis catheter (PDC), or percutaneous AVF (pAVF).

Evaluating 64 Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18 F-fluorodeoxyglucose PET/computed tomography.

Background: This study aimed to evaluate the biodistribution of 64 Cu-DOTA-rituximab and its diagnostic feasibility for lymphoma using CD20-targeted 64 Cu-DOTA-rituximab PET/computed tomography (PET/CT).

Methods: A prospective study involving six patients diagnosed with lymphoma was conducted between January 2022 and January 2023. These patients underwent 18 F-fluorodeoxyglucose ( 18 F-FDG) and 64 Cu-DOTA-rituximab PET/CT scans.